7,10,13-Eicosatrienoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7,10,13-Eicosatrienoic acid
• 英文别名: (7E,10E,13E)-icosa-7,10,13-trienoic acid
• 化学式: C₂₀H₃₄O₂
• 分子量: 306.5
• InChiKey: KSDMISMEMOGBFU-SPOHZTNBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  22
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Composition with Biofilm Dispersal Agents
  申请人：Vanderbilt University

  公开号：US20150182667A1

  公开（公告）日：2015-07-02

  Embodiments of the presently-disclosed subject matter provide composites that comprise a tissue graft and a biofilm dispersal agent. The tissue graft can be bone tissue graft, a soft tissue graft, or the like. In specific embodiments the tissue graft is a polyurethane graft and in other embodiments the tissue graft is bone particles, such as demineralized bone matrix. The biofilm dispersal agent can be one or more D-amino acids. The presently-disclosed subject matter further includes methods for treating tissue of a subject that comprise administering the present composites as well as methods for manufacturing the present composites.
• ENHANCED DELIVERY OF A HYDROPHOBIC AGENT IN THE ORAL CAVITY BY COUPLING TO A HYDROPHILIC AGENT WITH CELLULAR ACTIVITY
  申请人：Jernberg Gary R.

  公开号：US20200375935A1

  公开（公告）日：2020-12-03

  The compounds herein may be used to form an oral treatment composition. An oral treatment composition according to the present disclosure may comprise a mixture of different ingredients that when combined together result in an improved delivery mechanism to treat teeth and soft tissues of oral cavity. Generally the invention can be used to treat an oral disorder by delivering an oral treatment composition to a surface within the oral cavity, wherein the oral treatment composition comprises a hydrophobic active agent and a hydrophilic agent. The hydrophobic active agent may be a bacterial biofilm dispersion agent, a bacterial biofilm inhibitor, or a fatty acid signaling agent.
• PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME
  申请人：PLx Opco Inc.

  公开号：US20220000886A1

  公开（公告）日：2022-01-06

  Disclosed herein are novel drug carriers including a non-aqueous pH dependent release system and a non-aqueous pH dependent reassembly/assembly and reabsorption/absorption system. The carriers are capable of pH dependent release of biologically active agents and assembly or reassembly when the carrier transitions from a low pH environment, to a high pH environment and back to a low pH environment.
• ALBUMIN COMPOSITIONS AND METHODS OF PRODUCING AND USING SAME
  申请人：Albcura Corporation

  公开号：US20220048976A1

  公开（公告）日：2022-02-17

  Disclosed herein are albumin compositions having defined fatty acid profiles and methods of using the same. The albumin compositions described herein are suitable for use in cell culture methods, protein stabilization methods, amongst others. The albumin compositions described herein may improve the viability of and/or promote the growth of cells (e.g., mammalian cells) when the cells are cultured in a medium containing the albumin compositions. The albumin compositions described herein may improve the stability of a biologic when the biologic is in the presence of the albumin compositions. Further provided herein are methods of formulating albumin compositions having defined fatty acid profiles as described herein.
• NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION
  申请人：VICORE PHARMA AB

  公开号：US20220202729A1

  公开（公告）日：2022-06-30

  According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.